Glaucoma is a group of eye diseases that damage the optic nerve and can cause progressive vision loss if untreated. It is often asymptomatic in early stages and can lead to irreversible blindness. Early detection and intraocular pressure-lowering treatment are central to management.
Life Biosciences has treated the first patient with ER-100, a cell-rejuvenating gene therapy for glaucoma. The FDA-approved Phase 1 trial will assess safety in up to 18 patients.
A stem cell therapy for geographic atrophy improved vision in a phase Ib trial, and the first gene therapy for optic neuropathies was administered. Next-generation anti-VEGF agents are also extending treatment intervals in retinal vascular disease.
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, adding advanced retinal organoid and 2D RPE models to its iPSC portfolio. The deal follows Axol's acquisition of Phenocell and a $2.8 million financing led by BroadOak Capital Partners. Financial terms were not disclosed.
ARVO named Sangeetha Kandoi and Ellen Konadu Antwi-Adjei as the 2026 recipients of its annual Advocacy Awards. The honors recognize advocacy in eye and vision research and efforts to expand equitable access to care.
Researchers at Duke University discovered that specialized immune cells called resident macrophages maintain the eye's drainage system and regulate pressure, potentially providing a new therapeutic target for glaucoma treatment beyond current symptom management approaches.
The FDA cleared NexEos Bio's IND application to proceed with a Phase II/III trial of NTX-1024 ophthalmic solution for vernal keratoconjunctivitis, following positive results from a 15-patient study in Mexico.
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07771699 |
Cross-modal Neuromodulation to Improve Balance and Cognition in Older Adults With Glaucoma: A Randomized Trial of Cerebellar Transcranial Electrical Stimulation |
RECRUITING | NA |
| NCT07770685 |
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07769463 |
Impact of Meditation on Reducing Stress in Glaucoma Patients: An Electronic Feasibility Study |
NOT_YET_RECRUITING | NA |
| NCT07763288 |
Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Population in Bangkok |
COMPLETED | |
| NCT07758569 |
Validation of the Artificial Intelligence Subsystem of the DDART Medical Device for the Automated Detection of Lesions Compatible With Glaucoma in a Random Sample of Retinal Fundus Photographs |
RECRUITING | |
| NCT07755761 |
Innovative Tube Trabeculectomy for Advanced and Refractory Glaucoma: A Randomized Controlled Trial |
RECRUITING | NA |
| NCT07754201 |
VividFlo System Validation Study |
NOT_YET_RECRUITING | NA |
| NCT07739784 |
This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling. |
RECRUITING | |
| NCT07733453 |
Baerveldt Versus Paul Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT07733388 |
The Effectiveness Of Home-Based Circuit Training On Eye Pressure And Eye Nerve Structures In Patients With Glaucoma |
NOT_YET_RECRUITING | NA |
